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Thyroid dysfunction is an important public health problem, which affects 10% of the general
population and increases the risk of cardiovascular morbidity and mortality. Many aspects
of thyroid hormone regulation have only partly been elucidated, including its transport,
metabolism, and genetic determinants. Here we report a large meta-analysis of genome-wide
association studies for thyroid function and dysfunction, testing 8 million genetic variants in
up to 72,167 individuals. One-hundred-and-nine independent genetic variants are associated
with these traits. A genetic risk score, calculated to assess their combined effects on clinical
end points, shows significant associations with increased risk of both overt (Graves’ disease)
and subclinical thyroid disease, as well as clinical complications. By functional follow-up
on selected signals, we identify a novel thyroid hormone transporter (SLC17A4) and a
metabolizing enzyme (AADAT). Together, these results provide new knowledge about
thyroid hormone physiology and disease, opening new possibilities for therapeutic targets.
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Thyroid dysfunction is a common clinical condition,affecting ~10% of the general adult population1. Adequatethyroid hormone levels are essential for normal growth
and differentiation, regulation of energy metabolism, and phy-
siological function of virtually all human tissues. Thyroxine (T4)
is the prohormone produced by the thyroid, which is largely
converted into the active hormone 3,3′,5-triiodothyronine (T3) in
peripheral tissues. Circulating T4 levels are regulated by the
hypothalamus–pituitary–thyroid (HPT) axis, in which pituitary
thyroid-stimulating hormone (TSH) stimulates T4 production. In
turn, T4 and T3 negatively regulate TSH synthesis via a negative
feedback loop.
To exert their actions, T4 and T3 cross the membranes of
target cells via specific transporters. Once intracellular, they are
metabolized, including the conversion of T4 to T3, followed by
binding of T3 to its nuclear receptor to regulate transcription of
target genes. Both T4 and T3 transport and metabolism are
therefore key determinants of thyroid hormone action.
In daily clinical practice, thyroid function is assessed by mea-
suring circulating TSH and free T4 (FT4) levels, with increased
TSH indicating hypothyroidism and decreased TSH indicating
hyperthyroidism. FT4 levels are decreased in overt hypothyr-
oidism, increased in overt hyperthyroidism and in the reference
range in subclinical hypo and hyperthyroidism. In the last decade,
it has become clear that not only overt but also subclinical hypo
and hyperthyroidism are associated with several pathological
conditions, such as atrial fibrillation, coronary heart disease,
stroke, depression, as well as cardiovascular and overall mortal-
ity2–7. More recently, studies have shown that even variation in
thyroid function within the normal range is associated with many
of these complications4,8–10. Despite the physiological sig-
nificance of thyroid hormones, as well as the prevalence and
clinical importance of thyroid dysfunction, many key players in
the regulation of thyroid hormone bioavailability and action,
including its transport and metabolism, still need to be elucidated.
Genome-wide association studies (GWAS) performed so far
have revealed genetic variants in about 30 loci robustly associated
with thyroid function11–13. However, these variants explain only
<9% of the heritability of TSH and FT4 variation14, while in total,
it has been estimated at 65 and 39–80% for TSH and FT4,
respectively15,16, suggesting that many loci still await discovery.
Here, we report the results of a large meta-analysis of GWAS
for circulating TSH and FT4 levels, as well as for hypo and
hyperthyroidism, followed by independent replication and func-
tional studies. Results are complemented with genetic risk score
(GRS) analyses, gene expression, co-localization analyses, and
associations with various clinical phenotypes (Supplementary
Figure 1) to discover new pathways underlying thyroid function
and disease. We identify 109 significant independent genetic
associations with these traits. The GRS shows a significant asso-
ciation with increased risk of both Graves’ disease and subclinical
thyroid disease, as well as clinical complications. Finally, we
identify a novel thyroid hormone transporter and a metabolizing
enzyme. Together, these results enhance our knowledge about
thyroid hormone physiology and disease.
Results
New loci affecting thyroid hormone levels. Our GWAS meta-
analyses and replication in up to 72,167 subjects of European
ancestry with TSH levels within the reference range (Supple-
mentary Data 1) discovered 19 novel loci for circulating TSH
levels and 16 novel loci for circulating FT4 levels (Tables 1 and 2,
Supplementary Figures 2–5), leading to a total of 42 and 21
known and novel associated loci for these two traits. As illustrated
in Fig. 1, TSH and FT4 capture distinct and complementary
genetic underpinnings of thyroid function. Some of the novel loci
include genes that have been previously implicated in thyroid
development (GLIS3), thyroid hormone action and transport
(NCOR1, TTR, SLCO1B1), thyroid hormone metabolism (DIO2,
DIO3OS), and thyroid cancer (e.g., HES1, SPATA13, DIRC3, ID4)
by various candidate gene studies of monogenic diseases and
animal models. Multiple independent variants were found for
PDE8B, DIO1, DIO2, TSHR, and CAPZB.
Across the 42 TSH and 21 FT4 loci, allelic heterogeneity (i.e.,
independently associated single-nucleotide polymorphisms
(SNPs) at the same locus) was detected at 11 and 7 loci,
respectively, by using linkage structure information and summary
statistics-based conditional analyses (Supplementary Tables 1 and
2). All significant associations together accounted for 33% and
21% of the genetic variance of TSH and FT4, respectively,
explained by all common and low-frequency variants with a
minor allele frequency (MAF) >1%.
Since TSH and FT4 regulation are inversely correlated through
the HPT axis, we investigated the association of the TSH-
associated loci with FT4 levels, and vice versa. As shown in Fig. 1
and in Supplementary Tables 1 and 2, we observed overlapping
associations (Bonferroni-corrected threshold p < 8.2 × 10−4) at
various loci (TSH: FGF7, PDE8B, DET1, ITPK1, VEGFA, GLIS3,
NFIA, and MBIP, and FT4: FOXE1 and GLIS3), although only
GLIS3 showed genome-wide significance for both traits. All alleles
associated with higher TSH were associated with lower FT4, with
the exception of MBIP and FOXE1.
Hypo and hyperthyroidism are more prevalent in women than
in men. However, sex-stratified GWAS meta-analyses for TSH
and FT4 did not show any significant gene-by-sex interaction in
our samples (Supplementary Figure 6, Supplementary Tables 1
and 2).
Given the high degree of functional homology between the
mouse and human genome, we selected from The International
Mouse Phenotyping Consortium database17 genes that when
manipulated in mice cause abnormal thyroid physiology (i.e.,
hormone levels, n= 26) or morphology (n= 51), and assessed
whether their human homologs contained SNPs significantly (p <
2.5 × 10−5 for physiology and p < 1.9 × 10−5 for morphology, see
Methods) associated in our FT4 and TSH GWAS (Supplementary
Data 2). Of these candidate genes, SNPs in CGA (rs6924373) and
TPO (rs9678281) contained significant associations that did not
reach genome-wide significance in our GWAS for TSH. These
associations were tested for replication in 9011 independent
samples and achieved genome-wide significance for TSH (p < 5 ×
10−8) in the combined dataset (Supplementary Figure 7A).
Overall, these results highlight the potential of nested candidate
gene approaches in GWAS summary results and emphasize the
functional conservation of genes regulating thyroid function
between mice and humans.
Relation to hypo and hyperthyroidism. Genetic variants that
determine variation in circulating TSH and FT4 levels within the
reference range (i.e., the individual HPT-axis setpoint) are
expected to differ from variants that underlie thyroid dysfunction
(hypo or hyperthyroidism). To clarify this, we also conducted a
case–control GWAS meta-analysis of increased TSH levels (i.e.,
hypothyroidism), including cases with TSH levels above the
cohort-specific reference range (n= 3340) and controls with TSH
levels within the reference range (n= 49,983). The decreased TSH
level (i.e., hyperthyroidism) GWAS meta-analysis included cases
with TSH below the reference range (n= 1840 cases) and the
same controls as in the increased TSH GWAS. The distribution of
sex and age groups of these subjects is provided in Supplementary
Table 3. Since in both GWAS analyses, cases were defined on the
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basis of a TSH level above or below the reference range, these
groups included subjects with overt but also mild subclinical
forms of hypothyroidism and hyperthyroidism, respectively.
We detected seven loci for hypothyroidism and eight loci for
hyperthyroidism (Supplementary Figure 8, Supplementary
Table 4). At some of the loci, the variant was significantly
associated with both hypo and hyperthyroidism, with effects in
opposing directions. For example, a variant at PDE10A
(rs2983514) was associated with both higher risk of hypothyroid-
ism and lower risk of hyperthyroidism. Some of the hypothyroid-
ism loci had already previously been implicated in hypothyroidism
through GWAS, including TPO, FOXE1, VAV3, and a variant in
ATXN2 (rs597808) in high linkage disequilibrium (LD) with the
R262W polymorphism in SH2B318. However, we did not detect
variants in a number of well-known autoimmune thyroid disease
genes (e.g., CTLA4, HLA class I and II). This may be due to the
fact that, in these population-based cohorts, patients receiving
medication for autoimmune thyroiditis were excluded. Thus,
thyroid autoimmunity caused by auto-antibodies may have a
different set of predisposing variants. All variants associated with
hyperthyroidism have not been previously found in association
with hyperthyroidism, except for FOXE119. However, all of these
variants were in high LD with variants associated with TSH or
FT4 levels within the reference range in the current or previous
GWAS11,13. The same holds true for variants associated with
hypothyroidism, suggesting that the effects of many genetic
variants on thyroid function extend beyond the physiological
range, thus affecting the risk of thyroid dysfunction.
As complementary analyses to investigate whether the TSH loci
are also related to autoimmune thyroid diseases, we tested all
variants or their proxies for association with thyroid peroxidase
antibody (TPOAb) positivity of a former GWAS20 as an early
Table 1 Novel GWAS loci associated with TSH
SNP Chr:position Locus A1/
A2
AF1 Effect SE P I2 Phet N SNP function P
hyperthyroidism
P
hypothyroidism
rs6724073 2:218,236,786 DIRC3 t/c 0.74 0.045 0.007 3.1E−10 29.4 0.041 61058 Intron 1.1E−01 6.3E−02
rs28502438 3:149,220,109 TM4SF4 t/c 0.57 0.035 0.006 7.3E−10 0.0 0.853 63299 Intron 7.6E−01 7.2E−02
rs13100823 3:185,514,088 IGF2BP2 t/c 0.30 −0.042 0.006 4.1E−12 2.1 0.432 63299 Intron 8.5E−04 1.7E−04
rs59381142 3:193,916,181 HES1 a/g 0.24 −0.054 0.007 3.6E−15 0.0 0.801 61059 Unknown 1.8E−03 2.4E−02
rs1265091 6:31,108,129 PSORS1C1 t/c 0.19 0.058 0.007 5.0E−15 40.4 0.005 64423 Near gene-3 3.0E−01 3.0E−02
rs56009477 8:23,356,964 SLC25A37 a/g 0.84 0.050 0.008 1.1E−10 0.0 0.955 63299 Unknown 9.2E−03 3.5E−02
rs10957494 8:70,365,025 SULF1 a/g 0.69 −0.036 0.006 3.6E−09 21.4 0.111 63299 Unknown 3.5E−02 2.5E−01
rs118039499 8:133,771,635 TG a/c 0.97 0.185 0.020 2.9E−21 28.6 0.042 66615 Intron 1.8E−12 4.0E−01
rs2739067* 8:133,951,991 TG a/g 0.60 −0.042 0.006 2.4E−11 0.0 0.540 54288 Intron 1.2E−01 1.3E−01
rs9298749 9:16,214,340 C9orf92 a/c 0.59 −0.038 0.006 1.6E−10 10.4 0.280 63299 Unknown 9.0E−01 6.9E−03
rs11255790 10:8,682,180 GATA3 t/c 0.30 −0.039 0.006 2.5E−10 0.0 0.738 63299 Unknown 1.3E−02 7.9E−01
rs4933466 10:89,849,519 PTEN a/g 0.60 0.037 0.006 2.2E−10 24.3 0.079 63299 Unknown 2.6E−01 6.6E−03
rs4445669 11:115,045,237 CADM1 t/c 0.45 −0.039 0.006 3.6E−12 0.0 0.854 63299 Untranslated-3 5.1E−02 9.4E−02
rs7329958 13:24,782,080 SPATA13 t/c 0.35 −0.044 0.006 7.1E−14 0.0 0.913 63299 Intron 6.1E−01 4.5E−03
rs11159482* 14:81,490,842 TSHR t/c 0.09 0.085 0.013 6.3E−11 0.0 0.727 54288 Intron 1.9E−01 1.8E−04
rs59334515* 14:81,594,143 TSHR t/c 0.22 −0.054 0.007 1.1E−13 25.7 0.080 54288 Intron 1.4E−02 3.1E−03
rs12893151 14:81,619,945 TSHR a/c 0.21 −0.057 0.007 2.3E−15 27.4 0.052 63299 Unknown 3.2E−04 1.9E−04
rs1045476 16:4,015,313 ADCY9 a/g 0.17 0.047 0.007 3.2E−11 0.0 0.979 72167 Untranslated-3 1.7E−01 4.6E−03
rs30227 16:14,405,428 MIR365A t/c 0.61 −0.046 0.005 2.3E−17 3.0 0.415 72167 Intron 2.6E−02 1.1E−01
rs77819282 17:44,762,589 NSF a/g 0.24 0.043 0.007 4.3E−10 0.0 0.653 62192 Intron 5.2E−01 7.1E−03
rs1157994 17:59,338,574 BCAS3 a/g 0.05 −0.083 0.014 4.0E−09 21.0 0.120 59243 Intron 1.8E−01 4.1E−01
rs12390237 23:3,612,081 PRKX a/g 0.62 −0.046 0.007 1.7E−11 0.0 0.760 36501 Intron 1.0E−02 6.6E−01
The table contains the list of the index SNPs and additional independent associations of replicated TSH susceptibility loci. The values are provided for the combined discovery and replication sample, for
additional independent hits (*) for the discovery stage only
Bold values of the hyper and hypothyroidism p-values indicate significance after Bonferroni correction for the 61 independent TSH-associated SNPs tested (p < 8.2E−4)
A1 effect allele, AF1 allele frequency of A1, SE standard error of the effect, P association p-value, I² percentage of total variation across studies that is due to heterogeneity, N sample size
Table 2 Novel GWAS loci associated with FT4
SNP Chr:position Locus A1/A2 AF1 Effect SE P I2 Phet N SNP function
rs4954192 2:135,632,98 ACMSD t/c 0.43 −0.033 0.006 9.3E−09 2.6 0.424 62,680 Intron
rs6785807 3:181,718,601 SOX2-OT a/g 0.15 −0.057 0.009 6.9E−11 7.4 0.340 55,096 Intron
rs10946313 6:19,381,386 ID4 t/c 0.63 0.044 0.006 6.2E−12 0.0 0.907 55,096 Unknown
rs9356988 6:25,777,481 SLC17A4 a/g 0.27 −0.052 0.007 5.7E−14 0.0 0.745 55,096 Intron
rs137964359* 6:26,001,742 SLC17A4 t/c 0.99 −0.200 0.032 2.1E−10 0.0 0.479 49,269 Unknown
rs17185536 6:100,620,931 LOC728012 t/c 0.24 0.071 0.008 2.7E−20 0.0 0.973 53,801 Unknown
rs67583169 8:61,212,179 CA8 c/g 0.86 0.062 0.009 7.1E−12 0.0 0.936 53,801 Unknown
rs10119187 9:4,223,660 GLIS3 t/c 0.81 0.048 0.008 8.0E−10 6.4 0.357 56,936 Intron
rs10818937 9:127,015,440 NEK6 t/c 0.32 −0.039 0.006 4.9E−11 15.8 0.196 63,971 Unknown
rs11039355 11:47,737,501 FNBP4 t/c 0.34 −0.039 0.006 7.9E−11 12.2 0.258 62,677 Near gene-5
rs4149056 12:21,331,549 SLCO1B1 t/c 0.84 −0.048 0.007 6.3E−11 0.0 0.636 67,091 Missense
rs150816132* 14:80,464,293 DIO2 a/g 0.01 −0.220 0.040 3.5E−08 24.1 0.122 38,640 Unknown
rs978055* 14:80,534,869 DIO2 a/t 0.38 0.038 0.007 1.1E−08 10.5 0.296 49,269 Unknown
rs225014 14:80,669,580 DIO2 t/c 0.64 0.047 0.006 4.6E−17 0.0 0.702 63,971 Missense
rs12323871* 14:101,852,075 DIO3OS t/c 0.82 −0.047 0.008 1.4E−08 25.7 0.091 49,269 Unknown
rs11626434 14:101,998,443 DIO3OS c/g 0.36 0.053 0.007 1.7E−16 40.2 0.006 55,095 Unknown
rs12907106 15:63,873,658 USP3 c/g 0.27 −0.039 0.007 3.7E−08 0.0 0.529 53,801 Intron
rs8063103 16:12,703,395 SNX29 c/g 0.85 −0.051 0.009 7.8E−09 7.9 0.335 53,801 Unknown
rs11078333 17:16,049,626 NCOR1 a/t 0.51 0.042 0.006 2.0E−12 0.0 0.513 62,677 Intron
rs56069042 18:57,914,644 MC4R a/g 0.95 0.099 0.017 3.6E−09 0.0 0.735 58,197 Unknown
The table contains the list of the index SNPs and additional independent associations of replicated FT4 susceptibility loci. The values are provided for the combined discovery and replication sample, for
additional independent hits (*) for the discovery stage only
A1 effect allele, AF1 allele frequency of A1, SE standard error of the effect, P association p-value, I² percentage of total variation across studies that is due to heterogeneity, N sample size
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marker of autoimmune hypothyroidism, as well as in patients
with Graves’ disease (i.e., autoimmune hyperthyroidism) from the
BioBank Japan Project. For TPOAb positivity, significant
associations were found for MAF, SPATA13, and VAV3
(Supplementary Table 5). SPATA13 and VAV3 have previously
been linked to self-reported diagnosed hypothyroidism18,21, while
no studies have investigated their potential autoimmune origin.
The observed associations of these gene variants with variation in
TSH levels within the normal range could therefore be due to a
mild early stage of thyroid autoimmunity, instead of reflecting
physiological differences in the HPT-axis setpoint.
For Graves’ disease, only the psoriasis22 PSORS1C1 locus
showed a significant association, consistent with shared genetic
determinants between these two autoimmune diseases23.
Detailed results of the mouse candidate analysis, results of
pathway analyses, and look-ups for pleiotropy of the TSH, FT4,
hypo and hyperthyroidism loci are described in Supplementary
Note 1–3.
Gene expression analyses. To obtain insights into gene expres-
sion patterns and potential effector transcripts at the identified
loci, we assessed whether the 94 independent index variants from
the TSH, FT4, hypo and hyperthyroidism GWAS were correlated
with transcript levels of nearby (cis-) or distant (trans-) genes.
The results of 22 published expression quantitative trait loci
(eQTL) studies were interrogated (Methods), assessing the rela-
tion between the genetic variants and gene expression patterns in
a total of 127 different tissues and cell types. First, we evaluated
the presence of eQTLs in at least one tissue or cell type: 38
variants showed eQTL effects (Fig. 2a and Supplementary
Data 3). While many variants were associated with transcript
expression in only one or few (≤8) tissues, two variants located on
chromosome 17 showed ubiquitous associations with gene
expression: the FT4-associated variant rs11078333 at NCOR1
locus and the TSH-associated variant rs199461 at the NSF locus.
The FT4-increasing allele at rs11078333 was associated with
higher expression levels of NCOR1 in blood and brain, but also
affected the expression of ADORA2B (increased) and ZSWIM7
and TTC19 (decreased) in many other tissues (including thyroid
for TTC19). NCOR1 is an essential nuclear co-repressor that is
recruited by thyroid hormone receptors in the absence of thyroid
hormone to mediate transcriptional repression. At the NSF locus,
the TSH increasing allele at rs199461 increased expression of
KANSL1 and LRRC37A2 and decreased expression of WNT3 in
several tissues, including thyroid. Consistent with known thyroid
physiology, the majority of TSH-associated variants acted as
eQTLs in thyroid tissue (Fig. 2a), with 45% of the variants being
thyroid-specific eQTLs. In contrast, none of the nine FT4 eQTLs
acted exclusively on the thyroid but were also associated with
transcript expression changes in multiple known thyroid hor-
mone effector organs, including liver, muscle, and adipose tissue.
Second, we used a summary-based Mendelian randomization
(SMR) method coupled with testing for heterogeneity of effects
(HEIDI) to assess co-localization, i.e., to investigate whether the
overlap between eQTLs and GWAS hits could be attributable to
the same underlying causative variant24. In thyroid tissue, we
found evidence for co-localization with differential gene expres-
sion at 13 different GWAS loci: PD8EB, PRDM11, MBIP (with
RP11-116N8.1 expression), NKX2-3, NSF (with WNT3 expres-
sion), IGF2BP2, FOXA2, SLC25A37, and C9orf92 for TSH;
AADAT, NEK6 (with both NEK6 and PSMB7 expressions) for
FT4; and TPO, PDE8B, and PDE10A for hypothyroidism
(Supplementary Data 4). At these loci, our findings implicate
the causal gene among the many genes present in the locus. For
example, the FT4-associated variant rs6854291-influenced tran-
script levels of AADAT in thyroid while there were no effects on
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Fig. 1Manhattan plots for GWAS meta-analyses of thyroid function. Manhattan plots of the GWAS meta-analysis results for TSH and FT4 contrasted with
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transcript levels of the neighboring MFAP3L gene, implicating
AADAT as the causal gene underlying the FT4 association at this
locus (Fig. 2b, Supplementary Data 4). We also observed that
independent variants at the same locus were associated with gene
expression in different tissues. For example, while the index
variant rs6885099 at PDE8B co-localized with changes in PDE8B
expression in thyroid, the independent variant rs1119208 was
associated with PDE8B expression in pancreas (Supplementary
Data 4). Notably, also the variants at AADAT and SLC17A4 co-
localized with gene expression in pancreas (Fig. 2c), which is of
interest given the close interrelations between thyroid hormone
signaling, insulin regulation, and glucose metabolism25,26.
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loci, respectively. The upper box shows the regional association curve with FT4 levels, with level of significance of the SMR test (y axis) for each transcript
in the locus indicated by a diamond positioned at the center of the transcript. A significant SMR test indicates an association of the transcript level of the
respective genes with the trait. The lower box shows the regional association distribution with changes in expression of the highlighted transcript in
pancreas. In both boxes, x axis refers to GRCh37/hg19 genomic coordinates
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In vitro studies. Thyroid hormone action in target tissues is
importantly determined by the amount of T3 available for
receptor binding inside the cell. Therefore, the transport of
thyroid hormone across the cell membrane and its metabolism
inside the cell represent crucial regulatory layers in thyroid hor-
mone signaling. Although several key players in thyroid hormone
signaling have been described over the last decades, including
deiodinases and several thyroid hormone transporters, many
others remain to be identified. Based on their associations with
circulating FT4 levels and the co-localization studies, SLC17A4
and AADAT were further studied in vitro to explore a direct role
in thyroid hormone signaling.
SLC17A4 is an organic anion transporter that is particularly
expressed in the liver, kidney, and gastrointestinal tract27. We
transiently over-expressed human SLC17A4 (hSLC17A4) in COS-
1 cells and observed increased cellular T3 (Fig. 3a) and T4
(Fig. 3b) accumulation compared to empty-vector transfected
control cells. These effects were even stronger upon co-
transfection with the intracellular thyroid hormone-binding
protein mu-crystallin (CRYM) (Fig. 3a, b) and were similar in
magnitude to those obtained by the monocarboxylate transporter
(MCT) 8 (Supplementary Figure 9), the most specific thyroid
hormone transporter identified to date. Saturation experiments in
the absence of CRYM showed a dose-dependent decrease in the
uptake of T3 (Fig. 3c) and T4 (Fig. 3d). The estimated IC50 values
for T3 (0.35 ± 0.13 μM, n= 4) and T4 (0.06 ± 0.01 μM, n= 4)
transport by SLC17A4 are considerably lower than those of
MCT8 (T3: 20.61 ± 1.26 μM and T4: 23.22 ± 1.22 μM, n= 3,
Supplementary Figure 9), and other currently known thyroid
hormone transporters28–33, and indicate a high substrate affinity.
Together, these findings strongly indicate that SLC17A4 encodes a
high-affinity T3 and T4 transporter.
AADAT encodes a mitochondrial aminotransferase with broad
substrate specificity, which acts on kynurenic acid and α-aminoadi-
pate, important intermediates in tryptophan, and lysine metabo-
lism34,35. The association of circulating FT4 with the AADAT locus
suggested that AADAT may also be involved in thyroid hormone
metabolism. In that case, it could facilitate the oxidative deamination
of the alanine side-chain of thyroid hormone, yielding a pyruvic acid
moiety36. Therefore, lysates of AADAT over-expressing COS-1 cells
were incubated with T4 and T3 in the presence of the co-factor
pyridoxal phosphate and the co-substrate α-ketoglutaric acid, and the
reaction mixtures were analyzed by ultra-performance liquid
chromatography (UPLC). The results demonstrated effective time-
and AADAT concentration-dependent conversion of T4 and T3 to
their pyruvic acid metabolites TK3 and TK4 (Fig. 4), with saturation
occurring at substrate concentrations between 10 and 100 μM.
Importantly, this is well below the reported Km values of AADAT for
α-aminoadipate (0.9mM) and kynurenine (4.7mM)34.
Given the observed effects of SLC17A4 and AADAT on T3 and
T4 transport and metabolism, we additionally tested the
associations of the identified genetic variants in SLC17A4 and
AADAT with T3 levels and the T3/T4 ratio (Supplementary
Table 6). SLC17A4-rs9356988 was associated with the T3/T4
ratio, while AADAT-rs6854291 was associated with both the T3/
T4 ratio and T3 levels.
Genetic TSH and FT4 risk score associations. To assess the
cumulative clinical impact of our GWAS findings, we calculated a
weighted GRS for TSH and FT4 levels, which included all
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Fig. 3 Thyroid hormone transport by hSLC17A4. Cellular T3 (a) and T4 (b) accumulation in COS-1 cells, transiently transfected with empty vector (EV), or
wild-type hSLC17A4 in the absence (solid lines) or presence (dashed lines) of the intracellular thyroid hormone-binding protein CRYM, after indicated
incubation times at 37 °C. All uptake levels are expressed relative to the amount of radio-labeled T3 or T4 added to the cells at the start of the incubation
(1 nM (5 × 10E4 c.p.m.) [125I]-T3 or [125I]-T4). All results are presented as means ± SEM (n= 4). In the presence and absence of CRYM, T3 and T4
accumulation in hSLC17A4 transfected cells was significantly higher compared to empty-vector control cells at all time points (one-way ANOVA with a
Bonferroni-corrected post hoc test, p < 0.001). T3 (c) and T4 (d) saturation curves in COS-1 cells transiently transfected with hSLC17A4 in the absence of
CRYM. All data points are corrected for background thyroid hormone uptake in control cells and presented relatively to the amount of internalized thyroid
hormone in the presence of the lowest substrate concentration (0.003 µM for T3 and 0.001 µM for T4, respectively). Apparent IC50 values were
determined by standard second order polynomial regression analyses implemented in GraphPad Prism (La Jolla, USA)
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independent TSH- and FT4-associated variants, respectively.
Next, these GRSs were tested for association with the risk of
hypothyroidism and hyperthyroidism in up to 21,287 individuals.
Figure 5 shows substantial differences in the risk of thyroid
dysfunction across the range of GRS scores. Individuals with a
TSH-based GRS in the highest quartile compared to individuals
with a GRS in the lowest quartile had an odds ratio of 2.53 (p=
6.8 × 10−32) for hypothyroidism and 0.19 (p= 9.8 × 10−31) for
hyperthyroidism, respectively. Conversely, the FT4-based GRS
did not show any significant associations with either hypo or
hyperthyroidism (Supplementary Table 7), which is consistent
with the limited overlap observed between TSH and FT4 loci.
A GRS using all TSH-associated variants showed a significant
association with Graves’ disease (p= 2.9 × 10−5) that remained
significant after excluding the PSORS1C1 variant (p= 2.5 × 10−4),
indicating a polygenic contribution of TSH-associated variants
detected in the general population to Graves’ disease.
As normal thyroid function is essential for the physiological
function of virtually all human tissues, we tested if the TSH and
FT4 GRSs were associated with a broader range of phenotypes by
using available GWAS results of these phenotypes. These results
are shown in Supplementary Table 8 with effects provided per
increase in standard deviation of either TSH or FT4. A higher
TSH GRS was associated with both a lower risk of Graves’ disease
(odds ratio (OR)= 0.64, p= 2.0 × 10−5) and goiter (OR= 0.30, p
= 3.9 × 10−27), and lower thyroid volume (Δvol=−23%, p=
1.3 × 10−37), whereas a higher FT4 GRS was associated with a
higher risk of goiter (OR= 1.52, p= 7.9 × 10−3) and higher
thyroid volume (Δvol= 9%, p= 3.8 × 10−3). In addition, a higher
TSH GRS was associated with a lower risk of schizophrenia (OR
= 0.94, p= 0.01), shorter height (sd[height]:beta=−0.05, p=
2.0 × 10−11), and reduced kidney function (ΔeGFR=−1%, p=
1.4 × 10−5), as well as higher LDL (sd[LDL]:beta= 0.04, p=
4.9 × 10−3) and total cholesterol levels (sd[chol]:beta= 0.05, p=
1.1 × 10−5). A higher FT4 GRS was additionally associated with
taller height (sd[height]:beta= 0.04, p= 2.9 × 10−4), lower BMI
(sd[BMI]:beta=−0.04, p= 2.7 × 10−3), and lower LDL (sd
[LDL]:beta=−0.06, p= 3.1 × 10−4) and total cholesterol levels
(sd[chol]:beta=−0.05, p= 6.1 × 10−3) (Supplementary Table 9).
These associations match clinical and epidemiological
observations.
Discussion
With 8 million genetic variants tested in up to 72,167 individuals,
we present results of the largest GWAS on thyroid function and
dysfunction performed so far. We identified 109 significantly and
independently associated genetic variants, doubling the number
of loci known to regulate thyroid function, which explain a
substantial part of the variation in these traits. Importantly, we
detected associations between these variants and thyroid diseases
as well as various clinical end points, and functionally
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Fig. 4 AADAT converts T3 and T4 to their respective pyruvic acid metabolites. a shows the conversion of T3 and T4 to their pyruvic acid metabolites TK3
and TK4 in cell lysates of hAADAT over-expressing COS-1 cells. Cell lysates were incubated with [I125]-T3 or [I125]-T4 (2 × 105 c.p.m.) in the presence of
0.1 mM pyridoxal 5′-phosphate and 1 mM α-ketoglutaric acid for 30min and the resulting radio-labeled metabolites were separated by UPLC. The
conversion of T3 to TK3 depends on the incubation time (b) and amount of cell lysate added to the incubation reaction (c) and is saturated at substrate
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the UPLC column and is corrected for the TK3 production in lysates derived from empty-vector-transfected control cells (which was nearly absent). All
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characterized a new thyroid hormone transporter as well as a new
thyroid hormone metabolizing enzyme.
Almost all previously identified TSH and FT4-associated SNPs
were also genome-wide significantly associated with the respec-
tive trait in our analyses: the 20 TSH and 4 FT4 associations of
the sex-combined GWAS of Porcu et al.11, the two additional
TSH SNPs as well as the FT4 association revealed in Taylor
et al.12, and 17 of the 21 genome-wide significantly TSH-
associated SNPs identified by Gudmundsson et al.13 The
remaining loci of the latter study were discovered in our study via
the mouse candidate analysis and were also associated with
hypothyroidism (TPO), associated with FT4, hypo and hyper-
thyroidism (FOXE1), or had a p < 1 × 10−6 (FOXE1, ELK3,
SIVA1). Only two FT4-associated loci, LPCAT2/CAPNS2 and
NETO1/FBXO15, identified in the sex-stratified analysis of Porcu
et al. did not replicate in our sex-specific GWAS (p ≥ 0.01). While
all but 2 of the 18 cohorts (the Old Order Amish and the Balti-
more longitudinal study on Aging) of Porcu et al. as well as four
of the seven cohorts (TwinsUK GWAS, SardiNIA, Val Borbera
and BHS) of Taylor et al. were also included in our GWAS, we
more than doubled the sample size for both traits, thereby sig-
nificantly increasing our power to detect new loci.
Consistent with HPT-axis physiology, most TSH-associated
variants acted on gene expression levels in thyroid tissue, while
the FT4-associated variants had more widespread effects on
multiple known thyroid hormone target tissues. In addition, four
of the newly identified variants were either associated with the
risk of TPOAb positivity or Graves’ disease, suggesting an
underlying autoimmune-related pathophysiology. All of these
findings confirm that GWAS in the general population provides a
valuable method to identify genes implicated in thyroid phy-
siology and/or thyroid disease. Moreover, these insights can be
successfully translated into experimental evidence, as illustrated
by our in vitro studies on SLC17A4 and AADAT.
To investigate the combined effect of the thyroid hormone
associated risk variants, we calculated a GRS. The GRS of TSH-
associated variants was significantly associated with the risk of
hypothyroidism and hyperthyroidism. For some FT4-associated
hits, the lack of association with TSH levels can be explained on
physiological grounds. For example, the identified SNP in DIO1
decreases the enzymatic activity of the protein, leading to less T4
to T3 conversion, resulting in higher T4 levels, but lower T3
levels, resulting in no net effect on feedback to the pituitary and
therefore no effect on TSH levels. Similar hypotheses could be
postulated for other loci involved in thyroid hormone metabo-
lism, such as DIO3OS and AADAT. To assess whether these
genetically estimated TSH levels are clinically relevant or merely
reflect physiological inter-individual differences in TSH levels
(i.e., HPT-axis setpoint), we tested the GRS against various
clinical end points. These analyses showed significant associations
with thyroid diseases, and also with altered lipid levels (total and
LDL cholesterol) and height, which are both known to be affected
by hypo and hyperthyroidism. For example, short stature is one
of the key characteristics of patients suffering from congenital
hypothyroidism. Interestingly, associations were also found with
kidney function and schizophrenia, for which the causal rela-
tionships are less apparent. Thyroid hormone has been shown to
influence kidney development and filtration function37,38. Like-
wise, rodent and human studies have shown that both hypo and
hyperthyroidism lead to disrupted prenatal glial cell development,
which is an important step in the development of schizo-
phrenia39, while various psychiatric diseases including schizo-
phrenia are also thought to influence thyroid function via central
effects on the HPT axis40. Future studies are needed to clarify the
mechanisms underlying these associations, as it is not possible to
solve these potential inverse causal relationships solely with
GWAS results. Irrespective of the direction of the effects, our
results suggest that the presence of kidney dysfunction and psy-
chiatric symptoms in patients with thyroid disease deserve
attention. Given the substantial increase in number of TSH and
FT4-associated variants, which explain a substantial part of the
variation in these traits, future studies should start exploring the
use of these markers to predict the individual HPT-axis setpoint.
This predicted setpoint could be used to guide treatment of
thyroid diseases, which is important as despite normalized TSH
and FT4 levels, a substantial part of treated patients still have
persistent hypo or hyperthyroid complaints, leading to a lower
quality of life41. This could be due to the fact that the TSH and
FT4 levels are normalized to within the population-based refer-
ence ranges, but still deviate from the patient’s individual
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setpoint. For this purpose, a GWAS on the TSH/FT4 ratio could
prove to be a more sensitive method to identify more variants,
which specifically affect the HPT-axis setpoint.
When interpreting the results of our GWAS studies on increased
and decreased TSH levels, it is important to realize that these stu-
dies were performed in population-based cohorts, and not in
dedicated thyroid disease patient cohorts. Individuals on thyroid
medication or a history of thyroid surgery were excluded, resulting
in a relative overrepresentation of individuals with subclinical forms
of thyroid dysfunction. The identified variants are therefore
expected to be a mix of variants, which have been previously
associated with hypo or hyperthyroidism (e.g., TPO, FOXE1, and
ATXN2) and variants that lead to a TSH level, which is slightly
above or below the population-based reference ranges. These latter
effects can either reflect true mild thyroid dysfunction with
increased risk of clinical consequences or merely reflect a deviation
from the individual HPT-axis setpoint with no clinical con-
sequences. While our GRS analyses suggest that carrying multiple
risk alleles leads to an increased risk of overt thyroid dysfunction
and related clinical consequences, the exact contribution of each
individual variant needs to be clarified in future studies.
Thyroid hormone is importantly metabolized through enzy-
matic deiodination by DIO1-3, but also undergoes alternative
metabolic reactions, including conjugation with sulfate or glu-
curonic acid and modification of the alanine side-chain. The latter
includes the conversion of T3 and T4 to their respective pyruvic
acid metabolites TK3 and TK4, which requires the oxidative
deamination of their alanine side-chain36. TK3 and TK4 have
been detected in urine and bile of rat injected with radio-labeled
T3 and T442. Although these and other studies suggested an
important role for the liver and kidney in the formation of these
pyruvic acid metabolites, the involved enzyme(s) had not been
identified. Our functional analyses demonstrated that AADAT
effectively catalyzes the transamination of T4 and in particular T3
to TK4 and TK3, respectively. Moreover, AADAT is highly
expressed in the liver, gastrointestinal tract, and kidney in
human43. Taken together, AADAT activity may thus be critical for
the rate of thyroid hormone metabolism, which likely underlies
the association of AADAT with circulating FT4. Although the
specific impact of the associated variant on AADAT expression
has not been assessed yet, our eQTL co-localization studies indi-
cate that the index SNP decreases AADAT transcript levels in the
thyroid, and this in turn leads to increased circulating FT4 levels.
The functional analyses further demonstrate that human
SLC17A4 is able to transport both T4 and T3. The protein
belongs to the solute carrier 17 family, whose members transport
various organic anions, such as p-aminohippuric acid. Genetic
variation in the SLC17A4 locus has been associated with the
progression of elevated serum urate levels to gout27,44. According
to the GTEx data resource and previously reported studies27,
SLC17A4 is predominantly expressed in human small intestinal
and colonic epithelial cells, pancreas, liver, and kidney cortex,
which could imply a role for this transporter in the metabolic
clearance and entero-hepatic cycle of thyroid hormone. Future
studies should investigate the pharmacokinetic properties of
SLC17A4, its relative contributions to thyroid hormone transport
in various individual tissues, as well as the effects of the identified
SLC17A4 variants on thyroid hormone transport.
The findings from our functional studies do not only provide
new insights into thyroid hormone physiology, but may also have
important clinical implications. Hypothyroidism is treated with
levothyroxine (LT4), which is inexpensive and administered
orally. In recent decades, various factors have been identified
which help to determine LT4 dose, such as weight, gastrointestinal
diseases, and interfering drugs45,46. Despite this knowledge, inef-
fective LT4 supplementation is still a major clinical problem, as
30–50% of patients are either under- or over-treated and therefore
remain at risk for the symptoms and complications associated
with thyroid dysfunction45,46. Therefore, the identification of
SLC17A4 as a thyroid hormone transporter and AADAT as a
thyroid hormone metabolizing enzyme provides new insights into
thyroid hormone physiology and opens up a potential avenue for
novel therapeutic targets or optimization of existing ones to
improve the care of patients suffering from thyroid dysfunction.
All genetic findings in our study were limited to common or low-
frequency SNPs, whereas rare SNPs or structural variants may also
contribute to the yet unexplained variance of thyroid function.
Large whole-exome or -genome sequencing studies are required to
reveal these rare variant associations47. Furthermore, additional
GWAS with increased sample size will help to reveal the yet
undiscovered associations of common and low-frequency SNPs.
Our ThyroidOmics Consortium (http://www.thyroidomics.com)
provides a well-established infrastructure to address these
knowledge gaps in future projects.
Methods
Included studies. Discovery meta-analyses included data from 22 independent
cohorts with 54,288 subjects for the TSH analyses, and from 19 cohorts with
49,269 subjects for FT4, 53,423 subjects (3440 cases) for hypothyroidism, and
51,823 subjects (1840 cases) for hyperthyroidism (Supplementary Data 1). Selected
SNPs from the TSH or FT4 analyses were carried forward for replication with in
silico GWAS data from 5 cohorts (9053 subjects) and de novo genotyping in
additional 5 cohorts (13,330 subjects). All subjects gave informed consent and
studies were approved by the cohort-specific ethics committees.
We used the results of the GWAS of TPOAb positivity that included
18,297 subjects20 for a look-up of all the 53 TSH-associated loci or their HapMapII
proxies (r² > 0.8 in a 1Mb window) that were available in that dataset to assess
their relation to autoimmune hypothyroidism. A complementary look-up was
performed for the 52 SNPs that were available in a GWAS on Graves’ disease
diagnosed by clinical examinations, circulating thyroid hormone and TSH
concentrations, serum levels of antibodies against thyroglobulin, thyroid
microsomes, and TSH receptors, ultrasonography, [99m]TCO4− (technetium-99m
pertechnetate) (or [123I] (radioactive iodine)) uptake and thyroid scintigraphy
using the data of the BioBank Japan Project (BBJ) including 1747 patients and 6420
controls (Supplementary Data 1).
Trait definition. In each study, only subjects with TSH levels within the cohort-
specific reference range were included for the TSH and FT4 analyses. TSH and FT4
were analyzed as continuous variables after inverse normal transformation.
Increased TSH was defined by a TSH level above the upper limit of the cohort-
specific TSH reference range, while decreased TSH was defined by a level below the
lower limit of the reference range. For both increased and decreased TSH analyses,
the comparison group consisted of subject with a TSH level within the cohort-
specific reference range. Exclusion criteria for all analyses were non-European
ancestry, use of thyroid medication (defined as ATC (Anatomical Therapeutic
Chemical) code H03), or previous thyroid surgery.
GWAS in individual studies. In each study of the discovery GWAS, genotyping
was performed on genome-wide arrays. Genome-wide data were imputed to the
1000 Genomes, phase 1 version 3 (March 2012) ALL populations reference panel,
including the X chromosome. Quality control before imputation was applied in
each study separately. Details on study-specific genotyping and imputation infor-
mation are provided in the Supplementary Data 1.
In the individual study GWAS, the association of the SNPs was analyzed using
linear regression for TSH and FT4, and logistic regression for decreased and
increased TSH. The genotype–phenotype association was conducted using an
additive genetic model on SNP dosages, thus taking genotype uncertainties of
imputed SNPs into account. The analyses for TSH and FT4 were initially sex-
stratified and meta-analyzed as a second step. The analyses were adjusted for age,
age-squared (to account for non-linear effects), and relevant study-specific
covariates such as principal components for population stratification, study center,
and family structure (e.g., by inclusion of the kinship matrix as a random effect), if
applicable. The family-based cohorts GARP, SardiNIA, ValBorbera, MICROS,
TwinsUK, LLS, and FHS conducted additional analyses on the men and women-
combined sample, with additional adjustment for sex, to properly account for their
family relatedness.
Statistical methods for meta-analysis. Result files from individual studies
included in this analysis underwent extensive quality control before meta-analysis:
file format checks as well as plausibility and distributions of association results
including effects, standard errors, allele frequencies, and imputation quality of the
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SNPs were obtained by using the gwasqc() function of the GWAtoolbox package
v2.2.448. Additionally, the known associations of rs6885099 in PDE8B with TSH
and rs2235544 in DIO1 with FT4 were checked for consistent effect direction and
size in each study. All cohort-specific genomic control values (λGC) ranged from
0.94 to 1.14 (median 1.00) for the continuous trait and from 0.68 to 1.04 (median
0.91) for the dichotomous trait GWAS.
All meta-analyses were carried out in duplicate by three independent analysts.
We conducted a fixed-effect meta-analysis applying inverse-variance weighting as
implemented in Metal49. SNPs with MAF ≤0.005 or an imputation quality score
≤0.4 were excluded prior to the meta-analyses resulting in a median of 9,653,808
SNPs per cohort (IQR: 9,302,604–10,705,092). During the meta-analysis, the study-
specific results were corrected by their specific λGC if >1. Results were checked for
possible errors like use of incorrect unit, trait transformation, or association model
by plotting the association p-values of the analyses against those from a z-score-
based meta-analysis for verifying overall concordance. SNPs that were present in
<75% of the total sample size contributing to the respective meta-analysis
(separately for autosomal and X-chromosomal SNPs) or with a MAF ≤0.01 (hypo
and hyperthyroidism MAF ≤0.05 because of the low number of cases in the
analysis) were excluded from subsequent analyses. Finally, data for up to 8,048,941
genotyped or imputed autosomal and X-chromosomal SNPs were available after
the discovery stage meta-analysis of TSH, FT4, and up to 5,965,951 SNPs after
hypo and hyperthyroidism.
Quantile–quantile plots of the meta-analysis results are provided in
Supplementary Figures 10 and 11. To assess whether there was an inflation of p-
values in the meta-analysis results attributed to reasons other than polygenicity, we
performed LD score regression50. The LD score-corrected λGC values of the meta-
analysis results ranged from 1.00 to 1.04, supporting the absence of unaccounted
population stratification. Genome-wide significance was defined as a p-value of
<5 × 10−8, corresponding to a Bonferroni correction of one million independent
tests. Unless stated otherwise, all reported p-values are two-sided. The I2 statistic
was used to evaluate between-study heterogeneity51.
Gene-by-sex interaction on the circulating TSH and FT4 levels were obtained
for each SNP by comparing the discovery meta-analysis results from men (TSH: n
= 24,618; FT4 n= 22,315) and women using a t-test. Test statistics were calculated
using the formula t= (βmen− βwomen)/sqrt(SEmen²+ SEwomen²), assuming
independent effect sizes between men and women.
To evaluate the presence of independent SNPs within each locus, SNPs were
clustered based on their correlation with the SNP showing the lowest p-value at
that locus (index SNP) using the software PLINK52 and the genotypes of the
combined individuals of the 1000Genomes phase1v3 all ethnicities reference panel
(linkage disequilibrium pruning using r2 ≤ 0.01 within windows of ±1Mb). The
loci were named according to the nearest gene of the index SNP. Genomic
positions correspond to build 37 (GRCh37).
Replication analysis. The genome-wide significant index SNPs of newly identified
loci from the sex-combined TSH (n= 22) and FT4 meta-analyses (n= 19) were
taken forward to the replication stage (Supplementary Table 10). When SNPs were
not available in the in silico replication datasets, a proxy SNP in LD with r² > 0.8
was selected.
Of the ten studies that contributed to replication, five studies used
1000Genomes imputed dosages, three studies performed de novo genotyping, and
two studies were genotyped on both the Illumina ExomeChip and
CardiometaboChip. No SNP or proxy for the X-chromosomal locus was available
in any replication dataset. The results from the discovery meta-analysis and the
results of replication studies were meta-analyzed to obtain the overall p-values of
the selected SNPs. SNPs with p-values below genome-wide significance in this
combined analysis and with concordant effect directions in both stages were
considered as replicated53.
Integration of information from genetically manipulated mice. We tested
whether information about thyroid function or disease from genetically manipu-
lated mice could facilitate the detection of additional human thyroid loci that did
not reach genome-wide significance in the GWAS (nested candidate gene
approach). To this end, all genes that when manipulated cause abnormal thyroid
physiology (MP:0002876; 26 genes) or abnormal thyroid gland morphology
(MP:0000681; 51 genes) were selected from the comprehensive Mouse Genome
Informatics resource in October of 2016 (http://www.informatics.jax.org/mp/).
Next, genes were translated to their human homologs, followed by the calculation
of the number of independent SNPs in these genes with MAF > 0.01 in the 1000
Genomes EUR populations (PLINK option—indep-pairwise 50 5 0.2) to obtain
multiple testing corrected significance thresholds (p < 2.5 × 10−5 for physiology
and p < 1.9 × 10−5 for morphology). The genes in the respective mouse lists were
then queried for the presence of SNPs that showed association with TSH and/or
FT4 below the significance threshold. To test whether the number of genes with
significant associations was higher than expected by chance, results were compared
to those from 2000 iterations of random gene lists of equal length. A p-value for
enrichment was computed from a complementary cumulative binomial distribu-
tion as described in detail previously54. Lastly, novel loci that were not identified at
genome-wide significance in the GWAS of TSH or FT4 were tested for replication
in up to 9011 and 4532 independent samples for TSH and FT4, respectively.
Successful replication was defined as direction-consistent association and
genome-wide significance in a meta-analysis of the discovery and replication
samples.
eQTL look-up. To assess the possible effect of our lead signals on transcriptional
activity, we queried expression QTL (eQTL) results from 22 publicly available
studies (specific reference listed in Supplementary Data 3). These studies were
carried out from 2007 to February 2017 on 127 different tissues and cell types,
and used either micro-array or sequencing-based assessment of gene expression.
For each study, we derived the list of top eQTLs by LD clumping, and searched
top eQTLs in high LD (r2 > 0.8 in 1000Genomes EUR samples) with the 94 thyroid
function-associated index or independent SNPs (TSH, FT4, and ATXN2 and
TPO as additional GWAS loci from hypothyroidism) (Supplementary Tables 1, 2,
and 4).
To evaluate the evidence of co-localization between the index GWAS and eQTL
SNPs, we used the SMR method24, coupled with the test for heterogeneity of effects
(HEIDI)24. The first tests whether the effect on expression seen at a SNP or at its
proxies correlates with the signal observed in the GWAS (SMR test), while the
second evaluates if the eQTL and GWAS associations can be attributable to the
same causative variant (HEIDI test). Because direction of effects has to be taken
into account, we focused this analysis only on GTEx data for which full summary
results were available. For SMR, we considered the experiment-wise p-value of 2 ×
10−4 (corresponding to a Bonferroni correction for 242 gene-thyroid trait-tissue
combinations assessed). Specifically, we tested all genes with an eQTL p-value <1 ×
10−7 and for which the top eQTL showed genome-wide significant association with
any thyroid hormone traits, regardless of LD between the top eQTL and the thyroid
hormone index SNP. For the HEIDI test, we used the suggested p-value >0.05
cutoff to declare co-localization, and further required that at least five SNPs were
available for the test24.
Materials for in vitro studies. [125I]T3 and [125I]T4 were synthesized using the
standard chloramine-T method55. Unlabeled iodothyronines, pyridoxal 5′-phos-
phate (PLP), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), bovine
serum albumin, D-glucose, and Na2SeO3 were obtained from Sigma-Aldrich
(Zwijndrecht, The Netherlands); and α-ketoglutaric acid (KG) from Merck Milli-
pore (Amsterdam, NL).
Expression constructs and cloning. The cDNA of MCT8 and CRYM was cloned
into pcDNA3 and pSG5 expression vectors, respectively, using standard cloning
techniques56,57. A pCMV6-Entry_SLC17A4 expression vector containing a C-
terminal Myc and Flag tag was obtained from OriGene Technologies (Rockville,
USA). A pbluescript AADAT cDNA construct was obtained from Thermo Sci-
entific (Bleiswijk, NL) and subcloned into pcDNA3 with addition of a C-terminal
Flag-tag using standard cloning techniques. Any variants were substituted in
agreement with the NM_001286683.1 reference sequence using Quikchange site-
directed mutagenesis according to manufacturer’s protocol (Stratagene, Amster-
dam, The Netherlands). All primers are available upon request. Correctness of all
expression constructs was confirmed by sequencing of the inserts.
Cell culture and transfection. COS-1 African green monkey kidney cells
were obtained from ECACC (Sigma-Aldrich, Zwijndrecht, NL) and cultured in
DMEM/F12 (Life Technologies, Bleiswijk, NL) containing 9% heat-inactivated
fetal bovine serum (Sigma-Aldrich) and 0.2 mgmL−1 penicillin/streptomycin
(Life Technologies). Cell culture flasks and dishes were obtained from Corning
(Schiphol, NL).
For T3 and T4 uptake studies, COS-1 cells were seeded in 24-well dishes (1 ×
105 cells per well) and transiently transfected at 70% confluence with 250 ng empty
vector (EV), SLC17A4, or MCT8, with or without the addition of 100 ng CRYM.
CRYM is a cytoplasmic high-affinity thyroid hormone-binding protein, which
prevents efflux of internalized thyroid hormones. For thyroid hormone metabolism
assays, COS-1 cells were seeded on 10 cm dishes (5 × 105 cells per well) and
transiently transfected with 2000 ng EV or AADAT at 70% confluence. Xtreme-
Gene 9 was used as a transfection reagent according to manufacturer’s protocol
(Roche Diagnostics, Almere, NL).
Thyroid hormone uptake studies. Thyroid hormone uptake studies were per-
formed according to well-established protocols58,59. Cells were washed with
incubation medium (Dulbecco’s PBS (D-PBS) and 0.1% D-glucose) and incubated
for 10 min with 1 nM (5 × 104 c.p.m.) [125I]T3 or [125I]T4 in 375 μl incubation
medium at 37 °C. Finally, cells were washed once with incubation medium and
lysed with 0.1 M NaOH. Radioactivity in the lysates was measured with a γ-
counter. For saturation experiments, the indicated concentrations of unlabeled T3
or T4 were added to the incubation medium.
Thyroid hormone metabolism studies. Two days after transfection, cells were
harvested in 20 mM HEPES buffer (pH 7.5) and lysed by vortexing the sample for
30 s. Samples were clarified by centrifugation at 20,000×g for 30 min at 4 °C.
Thyroid hormone aminotransferase activity was measured in duplicate by
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incubating 0.1-100 μM of T3 or T4 in the presence of 2 × 105 c.p.m. 125I-labled
hormone for 5–60 min at 37 °C with 5–25 μl clarified lysate, 1 mM KG and 0.1 mM
PLP in a total volume of 100 μl HEPES buffer. Reactions were quenched by
addition of 125 μl ice-cold 0.1% acetic acid in acetonitrile, followed by 1 h of
incubation on ice to precipitate proteins. After centrifugation (20,000×g, 15 min, 4 °
C), 125 μl of the supernatant was mixed with 125 μl ammonium acetate buffer
(20 mM, pH 4.0), and 100 μl was analyzed by UPLC (Waters, Etten-Leur, NL)
using a BEH C18 reversed phase column (130 Å, 2.1 × 100 mm, 1.7 μm). Ammo-
nium acetate buffer (20 mM, pH 4.0, solvent A) and 0.1% acetic acid in
acetonitrile (solvent B) were used as mobile phase. Flow rate was 0.35 mLmin−1,
and column temperature 30 °C. The gradient used was: 0–1 min (30% B), 1–7 min
(30–42% B), 7–23 min (42–58% B), 25–27 min (58–100% B), and 27–32 min
(100–30% B). The radioactivity in the eluate was monitored using a Radiomatic A-
500 flow scintillation detector (Packard Instruments, Meriden, CT).
Genetic risk score analysis. Two separate GWAS effect size-weighted
GRS were generated to evaluate the combined effect of the TSH- and FT4-
increasing alleles, respectively, on the risk of hypo and hyperthyroidism using
individual level data from four of our largest GWAS studies: ARIC, CHS,
Rotterdam Study, and SHIP (hypothyroidism cases: n= 1613; hyperthyroidism
cases: n= 662; controls: n= 19,674). The GRS were based on the 61 and 31
replicated GWAS SNPs for TSH and FT4, respectively (Supplementary Tables 1
and 2), normalized to a range of 0 to 100, associated in each cohort separately
using a logistic regression adjusted for sex and age, and combined afterwards by
a fixed-effect inverse-variance meta-analysis using R60. The probability of disease
was calculated using the formula 1/(1+ exp(−(β0+ β1*x))), where β0 and β1
correspond to the intercept and GRS-related effect in the regression model,
respectively.
To test the combined effect of the replicated TSH and FT4 SNPs on various
traits (Supplementary Tables 8 and 9), a GRS-based association on meta-analyses
results was performed as described in reference61 using the function grs.summary()
of the R-package gtx. If a specific SNP was not available in the look-up GWAS
dataset, a proxy SNP in LD with r² > 0.8 was included where possible. The
association effects correspond to a change in the look-up GWAS trait (or natural
logarithm of the odds ratio in the case of a binary trait) per standard deviation unit
of TSH and FT4, respectively. In case the trait was logarithm-transformed in the
GWAS, (ebeta−1) × 100 corresponds to a 1% change of this trait.
Pathway analyses. We performed Data-Driven Expression Prioritized Integration
for Complex Traits (DEPICT)62 analyses to prioritize the most likely causal genes
at the associated loci and identify enriched pathways and tissues. We used DEPICT
version 1 rel194 and included variants with GC-corrected p-value <1 × 10−5 from
discovery GWAS as input. The following parameters were applied in the DEPICT
analyses: 50 repetitions used to compute the false discovery rate, 500 permutations
used to adjust for biases such as gene length, and 500 null GWAS used to run
repetitions and permutations.
Genes for network analysis were selected using the associated genes from
DEPICT using the lead SNPs from the analyses of the discovery GWAS. The
Ingenuity Pathway Analysis Software Tool (IPA; Ingenuity® Systems, CA, USA)
Network was used in order to perform pathway analysis (core analysis). Molecules
and/or relationships considered were the ones available in the IPA Knowledge Base
for mammals. Confidence filters considered only relationships, direct and indirect,
where the confidence is experimentally observed or high (predicted). Networks
were generated with a maximum size of 35 genes and allowing up to 25 networks
per analysis. We did not restrict for tissue and cell lines or mutations. The networks
are constructed using the IPA algorithm with the Ingenuity Knowledge Base as a
reference set generating a score as well as a p-value. IPA computes a score for each
network according to the fit of that network to the user-defined set of focus genes.
The score indicates the likelihood of the focus genes in a network being found
together due to random chance. The significance of p-value is calculated using the
right-tailed fisher exact test.
Look-up of pleiotropy. The look-up of additional traits associated with the
replicated GWAS findings were performed using the PhenoScanner63 database
with the default search options, whereas the independent SNPs of the replicated
TSH, FT4, hypo, and hyperthyroidism-associated loci or their proxies (r² > 0.8)
obtained by SNiPa64 were used as input. Look-up results with genome-wide sig-
nificant p-value (5 × 10−8) were reported.
Data availability
Summary genetic association results are available for full download or visualization on
the CHARGE dbGaP website under accession phs000930 (https://www.ncbi.nlm.nih.gov/
gap) and in the locuszoom web page: http://locuszoom.sph.umich.edu/genform.php.
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